Brazel, Danielle
Nagasaka, Misako http://orcid.org/0000-0001-5308-615X
Article History
Accepted: 12 March 2024
First Online: 13 May 2024
Declarations
:
: No external funding was used in the preparation of this manuscript.
: DB declares that she has no conflicts of interest that might be relevant to the contents of this manuscript. MN received consulting fees from Caris Life Sciences, honoraria from AstraZeneca, Daiichi Sankyo, Novartis, Lilly, Pfizer, EMD Serono, Genentech, Regeneron, and BMS. MN is a speaker for Mirati, Takeda, Janssen, and Blueprint Medicine and has received travel support from AnHeart Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: DB provided clinical interpretation and drafted and reviewed all versions of the manuscript. MN provided clinical interpretation and drafted and reviewed all versions of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.